Journal of Diabetes Science and Technology最新文献

{"title":"Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.","authors":"Viral N Shah, Anne L Peters, Guillermo E Umpierrez, Jennifer L Sherr, Halis Kaan Akturk, Grazia Aleppo, Lia Bally, Eda Cengiz, Ali Cinar, Kathleen Dungan, Chiara Fabris, Peter G Jacobs, Rayhan A Lal, Julia K Mader, Umesh Masharani, Priya Prahalad, Signe Schmidt, Eric Zijlstra, Cindy N Ho, Alessandra T Ayers, Tiffany Tian, Rachel E Aaron, David C Klonoff","doi":"10.1177/19322968241291512","DOIUrl":"10.1177/19322968241291512","url":null,"abstract":"<p><p>With increasing prevalence of obesity and cardiovascular diseases, there is a growing interest in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as an adjunct therapy in type 1 diabetes (T1D). The GLP-1RAs are currently not approved by the US Food and Drug Administration for the treatment of T1D in the absence of randomized controlled trials documenting efficacy and safety of these agents in this population. The Diabetes Technology Society convened a series of three consensus meetings of clinicians and researchers with expertise in diabetes technology, GLP-1RA therapy, and T1D management. The project was aimed at synthesizing current literature and providing conclusions on the use of GLP-1RA therapy as an adjunct to automated insulin delivery (AID) systems in adults with T1D. The expert panel members met virtually three times on January 17, 2024, and April 24, 2024, and August 14, 2024, to discuss topics ranging from physiology and outcomes of GLP-1RAs in T1D to limitations of current sensors, algorithms, and insulin for AID systems. The panelists also identified research gaps and future directions for research. The panelists voted to in favor of 31 recommendations. This report presents the consensus opinions of the participants that, in adults with T1D using AID systems, GLP-1RAs have the potential to (1) provide effective adjunct therapy and (2) improve glycemic and metabolic outcomes without increasing the risk of severe hypoglycemia or diabetic ketoacidosis.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241291512"},"PeriodicalIF":4.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of Cybersecurity/The Relevance of Cybersecurity to Diabetes Devices: An Update from Diabetes Technology Society.","authors":"Cindy N Ho, Alessandra T Ayers, Rachel E Aaron, Tiffany Tian, Chin-Sean Sum, David C Klonoff","doi":"10.1177/19322968241296543","DOIUrl":"10.1177/19322968241296543","url":null,"abstract":"<p><p>As medical devices become more integrated with wireless technologies, the risks of cyberattacks and data breaches increase, making stringent cybersecurity measures essential. The implementation of rigorous cybersecurity standards is essential for enhancing the cybersecurity of devices. This article examines the evolving cyber threats faced by the medical technology industry, the role of IEEE 2621 in providing comprehensive security benchmarks for medical devices, and the need for continuous risk assessments and adherence to regulatory standards to mitigate future cyber risks. Adherence to cybersecurity standards establishes ensures the effective protection of sensitive data and critical infrastructure.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241296543"},"PeriodicalIF":4.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effectiveness of Digital Health Lifestyle Interventions on Weight Loss in People With Prediabetes: A Systematic Review, Meta-Analysis, and Meta-Regression.","authors":"Tanja Fredensborg Holm, Flemming Witt Udsen, Iben Engelbrecht Giese, Kristine Færch, Morten Hasselstrøm Jensen, Bernt Johan von Scholten, Stine Hangaard","doi":"10.1177/19322968241292646","DOIUrl":"10.1177/19322968241292646","url":null,"abstract":"<p><strong>Background: </strong>Digital health lifestyle interventions (DHLI) may offer scalable solutions to manage prediabetes in clinical practice; however, their effectiveness on people with prediabetes has not been systematically investigated and reviewed. Hence, in this systematic review, meta-analysis, and meta-regression the effectiveness of DHLI on prediabetes-related outcomes was investigated.</p><p><strong>Methods: </strong>Four databases were searched to identify randomized controlled trials investigating the effectiveness of DHLI on adults with prediabetes published before 23 February 2024. The primary outcome was the change in body weight, with secondary outcomes including, among others, glycemic status, body composition, and feasibility outcomes. Meta-analyses were conducted to provide overall effect estimates of outcomes. In addition, meta-regressions on the primary outcome were conducted. The study quality was assessed using the Cochrane Risk of Bias tool, and the certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.</p><p><strong>Results: </strong>A total of 33 studies were included (n = 14 398). The study duration ranged from 3 to 60 months. The digital interventions varied from in-person meetings combined with pedometers and telephone calls to fully digital interventions. The overall estimated treatment difference in change in body weight favored the intervention (mean difference: -1.74 kg; 95% confidence interval: -2.37, -1.11; <i>P <</i> .01) with moderate certainty. Statistically significant overall effect estimates favoring the intervention were also found for secondary outcomes with very low to moderate certainty.</p><p><strong>Conclusion: </strong>Digital health lifestyle interventions can result in statistically significant change in body weight and other secondary outcomes among people with prediabetes.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241292646"},"PeriodicalIF":4.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Glycation End Products (AGEs) Webinar Meeting Report.","authors":"Cindy N Ho, Alessandra T Ayers, Paul Beisswenger, Stuart Chalew, Ann Marie Schmidt, Ambarish Pandey, Pankaj Kapahi, Alexander Fleming, David C Klonoff","doi":"10.1177/19322968241296541","DOIUrl":"10.1177/19322968241296541","url":null,"abstract":"<p><p>The advanced glycation end products (AGEs) Webinar was co-hosted by Diabetes Technology Society and Kitalys Institute on August 8, 2024, with the goal of reviewing progress made in the measurement and use of AGEs in clinical practice. Meeting topics included (1) AGEs as predictors of diabetic nephropathy (DKD), (2) hemoglobin glycation index (HGI) and the glycation gap (GG), (3) formation and structure of AGEs, (4) AGEs as a risk factor of cardiovascular disease (CVD), and (5) approaches to limit or prevent AGE formation.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241296541"},"PeriodicalIF":4.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Accuracy of a Continuous Glucose Monitoring System Across Varying Exercise Intensities and Blood Lactate Concentrations in Healthy Male Athletes.","authors":"Kristina Skroce, Lauren V Turner, Federico Y Fontana, Simone Bettega, Stefano Nardelli, Asker Jeukendrup, Howard C Zisser, Federico Schena, Cantor Tarperi, Michael C Riddell","doi":"10.1177/19322968241292363","DOIUrl":"10.1177/19322968241292363","url":null,"abstract":"","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241292363"},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Battery-Related Challenges in Insulin Pump Therapy: Insights From a Brazilian Diabetes Center.","authors":"Ana Lúcia Domingues Neves, Luiz Eduardo Galvão Martins, Mônica Andrade Lima Gabbay, Sebastião Vagner Arêdes, Fernanda Silva Tenorio, Karina Rabello Casali, Tatiana Sousa Cunha","doi":"10.1177/19322968241291877","DOIUrl":"10.1177/19322968241291877","url":null,"abstract":"","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241291877"},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Older Adults Benefit From Virtual Support for Continuous Glucose Monitor Use But Require Longer Visits.","authors":"Ruth S Weinstock, Dan Raghinaru, Robin L Gal, Richard M Bergenstal, Amy Bradshaw, Terra Cushman, Craig Kollman, Davida Kruger, Mary L Johnson, Teresa McArthur, Beth A Olson, Sean M Oser, Tamara K Oser, Roy W Beck, Korey Hood, Grazia Aleppo","doi":"10.1177/19322968241294250","DOIUrl":"10.1177/19322968241294250","url":null,"abstract":"<p><strong>Background: </strong>Older adults may be less comfortable with continuous glucose monitoring (CGM) technology or require additional education to support use. The Virtual Diabetes Specialty Clinic study provided the opportunity to understand glycemic outcomes and support needed for older versus younger adults living with diabetes and using CGM.</p><p><strong>Methods: </strong>Prospective, virtual study of adults with type 1 diabetes (T1D, N = 160) or type 2 diabetes (T2D, N = 74) using basal-bolus insulin injections or insulin pump therapy. Remote CGM diabetes education (3 scheduled visits over 1 month) was provided by Certified Diabetes Care and Education Specialists with additional visits as needed. CGM-measured glycemic metrics, HbA1c and visit duration were evaluated by age (<40, 40-64 and ≥65 years).</p><p><strong>Results: </strong>Median CGM use was ≥95% in all age groups. From baseline to 6 months, time 70 to 180 mg/dL improved from 45% ± 22 to 57% ± 16%; 50 ± 25 to 65 ± 18%; and 60 ± 28 to 69% ± 18% in the <40, 40-64, and ≥65-year groups, respectively (<40 vs 40-64 years <i>P</i> = 0.006). Corresponding values for HbA1c were 8.0% ± 1.6 to 7.3% ± 1.0%; 7.9 ± 1.6 to 7.0 ± 1.0%; and 7.4 ± 1.4 to 7.1% ± 0.9% (all <i>P</i> > 0.05). Visit duration was 41 min longer for ages ≥65 versus <40 years (<i>P</i> = 0.001).</p><p><strong>Conclusions: </strong>Adults with diabetes experience glycemic benefit after remote CGM use training, but training time for those >65 years is longer compared with younger adults. Addressing individual training-related needs, including needs that may vary by age, should be considered.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241294250"},"PeriodicalIF":4.1,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote Digital Technologies for the Early Detection and Monitoring of Cognitive Decline in Patients With Type 2 Diabetes: Insights From Studies of Neurodegenerative Diseases.","authors":"Ashley Y DuBord, Emily W Paolillo, Adam M Staffaroni","doi":"10.1177/19322968231171399","DOIUrl":"10.1177/19322968231171399","url":null,"abstract":"<p><p>Type 2 diabetes (T2D) is a risk factor for cognitive decline. In neurodegenerative disease research, remote digital cognitive assessments and unobtrusive sensors are gaining traction for their potential to improve early detection and monitoring of cognitive impairment. Given the high prevalence of cognitive impairments in T2D, these digital tools are highly relevant. Further research incorporating remote digital biomarkers of cognition, behavior, and motor functioning may enable comprehensive characterizations of patients with T2D and may ultimately improve clinical care and equitable access to research participation. The aim of this commentary article is to review the feasibility, validity, and limitations of using remote digital cognitive tests and unobtrusive detection methods to identify and monitor cognitive decline in neurodegenerative conditions and apply these insights to patients with T2D.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1489-1499"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9722144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond A1c: Investigating the Contribution of Red Blood Cell Parameters to Dysglycemia Diagnostics.","authors":"Simon Lebech Cichosz","doi":"10.1177/19322968241228541","DOIUrl":"10.1177/19322968241228541","url":null,"abstract":"","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1519-1520"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11529149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age and Red Blood Cell Parameters Mainly Explain the Differences Between HbA1c and Glycemic Management Indicator Among Patients With Type 1 Diabetes Using Intermittent Continuous Glucose Monitoring.","authors":"Pablo Azcoitia, Raquel Rodríguez-Castellano, Pedro Saavedra, María P Alberiche, Dunia Marrero, Ana M Wägner, Antonio Ojeda, Mauro Boronat","doi":"10.1177/19322968231191544","DOIUrl":"10.1177/19322968231191544","url":null,"abstract":"<p><strong>Background: </strong>Glycated hemoglobin (HbA1c) is the gold standard to assess glycemic control in patients with diabetes. Glucose management indicator (GMI), a metric generated by continuous glucose monitoring (CGM), has been proposed as an alternative to HbA1c, but the two values may differ, complicating clinical decision-making. This study aimed to identify the factors that may explain the discrepancy between them.</p><p><strong>Methods: </strong>Subjects were patients with type 1 diabetes, with one or more HbA1c measurements after starting the use of the Freestyle Libre 2 intermittent CGM, who shared their data with the center on the Libreview platform. The 14-day glucometric reports were retrieved, with the end date coinciding with the date of each HbA1c measurement, and those with sensor use ≥70% were selected. Clinical data prior to the start of CGM use, glucometric data from each report, and other simultaneous laboratory measurements with HbA1c were collected.</p><p><strong>Results: </strong>A total of 646 HbA1c values and their corresponding glucometric reports were obtained from 339 patients. The absolute difference between HbA1c and GMI was <0.3% in only 38.7% of cases. Univariate analysis showed that the HbA1c-GMI value was associated with age, diabetes duration, estimated glomerular filtration rate, mean corpuscular volume (MCV), red cell distribution width (RDW), and time with glucose between 180 and 250 mg/dL. In a multilevel model, only age and RDW, positively, and MCV, negatively, were correlated to HbA1c-GMI.</p><p><strong>Conclusion: </strong>The difference between HbA1c and GMI is clinically relevant in a high percentage of cases. Age and easily accessible hematological parameters (MCV and RDW) can help to interpret these differences.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1370-1376"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11529079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10332762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}